No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
www.lundbeck.comNo one on the platform currently holds HLUN-B.CO.
No tracked institution reports a position in HLUN-B.CO as of their last filing.
No one on the platform has traded HLUN-B.CO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.5% | 10.0% | 14.7% | — | — | — |
| Rev. Growth % | 10.7% | 6.6% | ||||
| Profit Margin % | 13.1% | 11.5% | 12.7% | |||
| Free Cash Flow Margin % | 17.8% | 14.7% | 17.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $25.9B | +5.6% | $4.68 | $3.36–$4.95 | — | 9 |
| 2027 | $25.9B | +0.2% | $4.70 | $3.92–$5.17 | — | 10 |
| 2028 | $25.3B | -2.4% | $4.35 | $3.25–$5.24 | — | 9 |
| 2029 | $23.2B | -8.5% | $3.98 | $3.81–$4.16 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-19 | $1.11 | $1.16 | +4.5% |
| 2026-05-12 | $1.40 | $1.67 | +19.3% |
| 2026-02-03 | $0.72 | $0.05 | -93.1% |
| 2025-11-11 | $0.87 | $1.11 | +27.0% |
| 2025-08-14 | $0.95 | $0.97 | +1.7% |
| 2025-05-14 | $0.90 | $1.16 | +29.6% |
| 2025-02-05 | $0.42 | $0.60 | +41.9% |
| 2024-11-13 | $1.29 |
| $0.78 |
| -39.5% |
| -3.46% |
| $552M |
| — |
| CHEMM.COChemoMetec A/S | $492.40 | +1.95% | $8.6B | — |
| DEMANT.CODemant A/S | $295.80 | -0.80% | $62.4B | — |
Source: Financial Modeling Prep · peers by sector/industry